Cardiol Therapeutics Inc. Class A Common Shares (CRDL) Stock Price

CRDLStock

$2.00+59.26%52W

Market Cap$233.65M

P/E—

PEG Ratio—

Div yield—

Beta2.31

CRDL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)66.69%

Price vs S&P 500 (4W)54.27%

VGM Score80.61

Book Value / Share (Quarterly)$0.16

P/TBV (Annual)6.12x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.16

Price vs S&P 500 (YTD)85.82%

EPS (TTM)$-0.28

10-Day Avg Trading Volume0.27M

EPS Excl Extra (TTM)$-0.28

EPS (Annual)$-0.37

ROI (Annual)-147.38%

Net Profit Margin (5Y Avg)-143204.20%

Cash / Share (Quarterly)$0.18

ROA (Last FY)-115.11%

EBITD / Share (TTM)$-0.27

ROE (5Y Avg)-100.84%

Cash Flow / Share (Annual)$-0.17

P/B Ratio10.15x

P/B Ratio (Quarterly)8.73x

Net Income / Employee (Annual)$-1,472,293

Net Interest Coverage (TTM)-0.89x

ROA (TTM)-165.39%

EPS Incl Extra (Annual)$-0.37

Current Ratio (Annual)4.16x

Quick Ratio (Quarterly)3.93x

3-Month Avg Trading Volume0.11M

52-Week Price Return59.26%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.22

P/S Ratio (Annual)3070.95x

Asset Turnover (Annual)0.00x

52-Week High$1.99

Operating Margin (5Y Avg)-156141.00%

EPS Excl Extra (Annual)$-0.37

CapEx CAGR (5Y)-9.35%

Tangible BV CAGR (5Y)11.86%

26-Week Price Return77.93%

Quick Ratio (Annual)3.83x

13-Week Price Return41.76%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)4.39x

Enterprise Value$157.60M

Book Value / Share Growth (5Y)-15.08%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-39550.00%

Cash / Share (Annual)$0.15

3-Month Return Std Dev58.14%

Net Income / Employee (TTM)$-1,459,142

ROE (Last FY)-148.32%

Net Interest Coverage (Annual)-9.71x

EPS Basic Excl Extra (Annual)$-0.37

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.28

Receivables Turnover (Annual)0.00x

ROI (TTM)-227.30%

Pretax Margin (5Y Avg)-143204.20%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.22

Price vs S&P 500 (52W)40.95%

Year-to-Date Return96.95%

5-Day Price Return-1.15%

EPS Normalized (Annual)$-0.37

ROA (5Y Avg)-81.50%

Net Profit Margin (Annual)-39550.00%

Month-to-Date Return46.59%

Cash Flow / Share (TTM)$-0.31

EBITD / Share (Annual)$-0.40

Operating Margin (Annual)-48325.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-100.13%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.28

P/TBV (Quarterly)6.12x

P/B Ratio (Annual)7.33x

Book Value / Share (Annual)$0.13

Price vs S&P 500 (13W)38.96%

Beta2.31x

Revenue / Share (TTM)$0.00

ROE (TTM)-229.16%

52-Week Low$0.89

mGradeA

vgmGradeA

CRDL Earnings Surprise History

Q2 25-0.07est. -0.09

Q3 25-0.09est. -0.08

Q4 25-0.05est. -0.08

Q1 26-0.07est. -0.07

Q2 26-0.04est. -0.07

CRDL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

4.13

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRDLCardiol Therapeutics Inc. Class A Common Shares	—	—	A	$2.00
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Cardiol Therapeutics Inc. Class A Common Shares

Cardiol Therapeutics is a late-stage biopharmaceutical company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, is advancing through Phase III trials for pericarditis treatment and has completed Phase II studies in myocarditis and heart failure. The company is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart conditions.